Week of December 3, 2012: Biogen Idec Opens New RTP Facility; Tekmira, Marina Biotech Enter into License Agreement for UNA Technology; and More - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Week of December 3, 2012: Biogen Idec Opens New RTP Facility; Tekmira, Marina Biotech Enter into License Agreement for UNA Technology; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Biogen Idec has opened its new facility in Research Triangle Park (RTP), North Carolina, consolidating its 300-person patient-services operation with the existing RTP campus. The new 190,000-ft2 building is anticipated to achieve LEED-Gold certified status in the next several months and will accommodate increasing levels of manufacturing activity at the site. The official groundbreaking for the building took place in April 2011. Read More

Tekmira Pharmaceuticals, a developer of RNA interference (RNAi) therapeutics, has obtained a worldwide, nonexclusive license to an RNAi payload technology called Unlocked Nucleobase Analog (UNA) from Marina Biotech for the development of RNAi therapeutics. UNA technology can be used in the development of RNAi therapeutics, which treat disease by silencing specific disease-causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects. Read More

TOT Biopharm has completed an 18-month construction project in the first stage of its $100-million factory complex in eastern China’s Suzhou Industrial Park. The factory complex specializes in the R&D, production, and marketing of anticancer drugs globally. The first stage of TOT Biopharm’s new factory complex includes an oral anticancer drug plant with separate production facilities for both cytotoxics and noncytotoxics, an injected anticancer drug plant, and a GMP bio pilot plant with a capacity of 500 L for cell culture, purification, and filling. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here